An Open Label Evaluation of the Dose Proportionality of Dilaudid SR (OROS Hydromorphone HCL) Tablets 8mg, 16mg, 32mg, and 64mg.

Trial Profile

An Open Label Evaluation of the Dose Proportionality of Dilaudid SR (OROS Hydromorphone HCL) Tablets 8mg, 16mg, 32mg, and 64mg.

Completed
Phase of Trial: Phase I

Latest Information Update: 14 Jul 2009

At a glance

  • Drugs Hydromorphone (Primary)
  • Indications Pain
  • Focus Pharmacokinetics
  • Sponsors ALZA Corporation
  • Most Recent Events

    • 14 Jul 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 27 Nov 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top